Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article22 days agoDaratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, Meletios A Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksaç, Keith Stockerl‐Goldstein, Hila Magen, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Simon Hallam, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Abid Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-372.
Article22 days agoP-363 Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ≥65 Years From Both PERSEUS and GRIFFIN Studies
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2024). P-363 Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ≥65 Years From Both PERSEUS and GRIFFIN Studies. , 24, DOI: https://doi.org/10.1016/s2152-2650(24)02265-1.
Article22 days ago